Zofran - Drug Monograph

Introduction

Zofran (ondansetron) is a selective 5-HT₃ receptor antagonist used principally for the prevention and treatment of acute chemotherapy-induced nausea and vomiting (CINV), postoperative nausea and vomiting (PONV), and radiation-induced nausea and vomiting (RINV). It is one of the most widely prescribed antiemetics in clinical practice due to its favorable efficacy and safety profile compared with older antiemetics such as metoclopramide. Its clinical relevance extends across oncology, anesthesiology, emergency medicine, and obstetrics, where it is also commonly used off-label for nausea and vomiting of pregnancy.

Drug Class and Overview

• Class: Selective serotonin (5-HT₃) receptor antagonist antiemetic.
• Related agents: Granisetron, dolasetron, and palonosetron. Palonosetron is distinguished by a longer half-life and greater 5-HT₃ receptor binding affinity.
• Distinguishing features: Ondansetron is a racemic mixture; it does not have meaningful affinity for dopamine, histamine, or muscarinic receptors at therapeutic doses, which contributes to a lower incidence of sedation, extrapyramidal symptoms, and anticholinergic effects compared with agents such as prochlorperazine or metoclopramide. It is available in multiple formulations (oral tablets, orally disintegrating tablets, oral solution, and intravenous).

Mechanism of Action

Ondansetron competitively antagonizes serotonin 5-HT₃ receptors located both peripherally on vagal afferent fibers of the gastrointestinal tract and centrally in the chemoreceptor trigger zone of the area postrema. Blockade prevents serotonin-mediated activation of the vomiting reflex. The antiemetic effect is particularly pronounced against acute (≤24 hours) emesis triggered by highly emetogenic stimuli such as cisplatin-based chemotherapy, where enterochromaffin cell release of serotonin plays a central role.

Indications

• Prevention of nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy, including cisplatin.
• Prevention of postoperative nausea and vomiting (PONV) in adults and (age-restricted) pediatric patients.
• Prevention of nausea and vomiting associated with radiation therapy, particularly total body irradiation and fractionated abdominal radiation.
• Prevention and treatment of postoperative nausea and vomiting after surgery.
• Commonly used (off-label in the United States) for nausea and vomiting of pregnancy, particularly after first-trimester exposure concerns (see Warnings).

Dosage and Administration

Typical adult dosing (varies by indication):

• Chemotherapy-induced nausea and vomiting (highly emetogenic):
• Oral: 24 mg single dose 30 minutes before chemotherapy (single-day regimens).
• Intravenous: 8–16 mg infused over 15 minutes beginning 30 minutes before chemotherapy.
• Moderately emetogenic chemotherapy: 8 mg orally twice daily or 8 mg IV.
• Radiation-induced nausea and vomiting: 8 mg orally three times daily.
• Postoperative nausea and vomiting (adults): 4 mg IV/IM (or 8 mg orally) given as a single dose; may repeat for inadequate control.

Renal/Hepatic adjustment: Severe hepatic impairment (Child-Pugh C) — total daily dose should not exceed 8 mg IV or 8 mg orally.

Pediatric (≥1 month for CINV; ≥1 month for PONV per labeling history): 0.15 mg/kg IV (max 8 mg) every 4 hours for up to 3 doses.

Pregnancy: Considered relatively safe; commonly used off-label for NVP (see Warnings).

Geriatric: No routine dose adjustment beyond standard adult recommendations.

Pharmacokinetics

• Absorption: Oral bioavailability is approximately 60–70% due to first-pass metabolism; peak plasma concentrations occur in 1–1.5 hours.
• Distribution: Widely distributed; plasma protein binding is approximately 70–76%. Volume of distribution is roughly 1.9 L/kg (IV).
• Metabolism: Hepatic, primarily via CYP3A4, with minor contributions from CYP2D6 and CYP1A2. It is also a substrate of P-glycoprotein.
• Elimination: Renal and hepatic routes, with less than 5% excreted unchanged. Plasma clearance is ~0.35 L/h/kg.
• Half-life: Approximately 3–4 hours in healthy adults, prolonged to ~9–20 hours in severe hepatic impairment.

Contraindications

• Concomitant use with apomorphine (risk of profound hypotension and loss of consciousness).
• Known hypersensitivity to ondansetron or any component of the formulation.

Warnings and Precautions

• QT prolongation / Torsades de pointes: Dose-dependent QTc prolongation has been documented. Use with caution in patients with electrolyte abnormalities (hypokalemia, hypomagnesemia), congestive heart failure, bradyarrhythmias, or those taking other QT-prolonging medications. IV ondansetron should be avoided in patients with congenital long QT syndrome.
• Serotonin syndrome: Reported risk when used in combination with other serotonergic drugs (e.g., SSRIs, SNRIs, MAO inhibitors, tramadol, linezolid, methylene blue). Monitor for autonomic instability, neuromuscular hyperactivity, and altered mental status.
• Pregnancy and QT effects: In 2016 the FDA removed the prior contraindication for use in pregnancy, but labels include pregnancy-specific warnings about fetal cardiovascular effects observed in some early studies.
• Anaphylaxis / hypersensitivity reactions: Rare but reported, including bronchospasm, angioedema, and anaphylactic shock.
• Hepatic impairment: Reduced clearance; dose adjustment recommended.
• Masking of progressive ileus or gastric distension in post-operative abdominal surgery patients.

Drug Interactions

• Apomorphine: Contraindicated due to severe hypotension and syncope.
• QT-prolonging agents (antiarrhythmics, certain antipsychotics, fluoroquinolones, class IA and III antiarrhythmics): Additive QTc prolongation risk.
• Serotonergic drugs (SSRIs, SNRIs, MAOIs, TCAs, tramadol, linezolid): Increased risk of serotonin syndrome.
• CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine, St. John's wort): May reduce ondansetron levels and effectiveness.
• Tramadol: Combined use may reduce tramadol's analgesic efficacy (limited clinical significance).
• Dopamine antagonists (e.g., metoclopramide): Additive antiemetic effect; no clear pharmacokinetic interaction.

Adverse Effects

• Common (>10%): Headache, constipation, fatigue.
• Less common (1–10%): Dizziness, drowsiness, diarrhea, dry mouth, flushing, injection-site reactions.
• Serious/rare (<1%): QT prolongation, torsades de pointes, serotonin syndrome, anaphylaxis, bronchospasm, transient elevations in hepatic transaminases, Stevens-Johnson syndrome (very rare reports).

Monitoring Parameters

• ECG in high-risk patients (those on other QT-prolonging drugs, with structural heart disease, electrolyte disturbances, or congenital long QT syndrome).
• Serum electrolytes (potassium, magnesium) before IV dosing in at-risk patients.
• Clinical assessment of emesis control and bowel function (constipation is dose-related).
• Hepatic function in patients with severe liver disease.
• Mental status and neuromuscular examination if combined with serotonergic agents (serotonin syndrome screening).

Patient Education

• Take oral doses exactly as prescribed, usually 30 minutes before chemotherapy or at the scheduled times for radiation-induced nausea.
• For the orally disintegrating tablet (ODT), place on the tongue; it dissolves within seconds — do not push through the blister pack until ready to use.
• Report palpitations, fainting, severe dizziness, or unusual involuntary movements immediately.
• Constipation is common; ensure adequate hydration and fiber intake, and report persistent constipation.
• If you are taking an antidepressant (SSRI/SNRI), inform your clinician, since combination therapy may rarely cause serotonin syndrome (agitation, tremor, sweating, confusion).
• Pregnant patients should discuss use with their obstetric provider; ondansetron is widely used for NVP after first trimester per professional society guidance.

Clinical Pearls

1. High-dose IV (>16 mg) ondansetron is associated with measurable QT prolongation; many institutions now cap single IV doses at 16 mg (often 8 mg in pediatric protocols) to mitigate arrhythmia risk.
2. Ondansetron works best for acute (<24 h) emesis; for delayed CINV, NK-1 receptor antagonists (e.g., aprepitant) plus dexamethasone are superior.
3. The FDA removed the prior contraindication in pregnancy (2016) but labeling still includes fetal-risk language; ACOG supports its use after the first trimester for severe NVP unresponsive to first-line therapy (vitamin B₆ + doxylamine).
4. Dose reduction is essential in severe hepatic impairment because clearance is heavily dependent on hepatic CYP3A4 metabolism.
5. Serotonin syndrome risk is rare but real when combined with SSRIs/SNRIs; clinicians should monitor for hyperreflexia, clonus, and autonomic instability.
6. Ondansetron is not effective for motion sickness because motion sickness is mediated primarily by histaminergic and muscarinic pathways, not serotonergic ones.

References

1. U.S. Food and Drug Administration. Zofran (ondansetron hydrochloride) Prescribing Information. GlaxoSmithKline. (Most recent label revision.)
2. American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 189: Nausea and Vomiting of Pregnancy. Obstetrics & Gynecology. 2018 (reaffirmed).
3. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Antiemesis. (Current version.)
4. Gan TJ, et al. Consensus Guidelines for the Management of Postoperative Nausea and Vomiting. Anesthesia & Analgesia. 2020.
5. Roila F, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Annals of Oncology. 2016.
6. Brunton LL, Knollmann BC (eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics. McGraw-Hill (standard pharmacology reference; 14th edition).
7. Lexicomp Online. Ondansetron: Drug Information. Wolters Kluwer. (Accessed for clinical reference.)
8. PubChem / National Library of Medicine. Ondansetron Compound Summary. NIH. https://pubchem.ncbi.nlm.nih.gov/compound/Ondansetron
9. Tramer MR, et al. Efficacy, dose-response, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review. Anesthesiology. 1997.
10. U.S. Food and Drug Administration. Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran). 2011/2016.